The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) targeting CD19 and BCMA works to treat refractory SLE in adults. It will also learn about the safety and efficacy of the UCAR-T cell product.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Chengdu Ucello Biotechnology Co., Ltd.
Collaborators:
The General Hospital of Western Theater Command Yancheng Third People's Hospital